Its only a matter of time when we see the value in this...

Its only a matter of time when we see the value in this relationship. Being the first to have pharmaceutical products in Australia will make Canndeo the leader in the industry.


The Hydroponics Company (ASX:THC) through its subsidiary Canndeo is well on track in its development of medicinal cannabis solutions for the Australian market.
The commercial environment for medicinal cannabis is changing evidenced by the recent vote in the Australian Senate enabling increased access to medicinal cannabis for terminally ill patients.

The change enables medical practitioners to seek importation of unapproved medicines for terminally ill patients without obtaining approval in advance from the Therapeutic Goods Administration (TGA).
Since the Senate vote on June 13, Canndeo has engaged with Phoenix Life Science, a Colorado-based healthcare company, to provide medicinal cannabis to meet this need.

Phoenix Life is currently building production facilities to export cannabidiol products from North America and through their alliance with Canndeo, these products will be available in Australia.
Subject to government approval, THC aims to import medicinal cannabis products with targeted availability from the December quarter 2017, which fits neatly with the regulatory change.
THC shares are trading over 40% higher than their ASX-listing price, currently priced at $0.285.
Share